a clinical research to compare the effect of mur with mefenamic acid in painful menses.

Efficacy of Mur (Commiphoramyrrha) in Usretamas- A Randomized Single Blind Standard Control trial.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009596

Enrollment

Registered

2017-09-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- primary dysmenorrhoea

Interventions

Intervention1: Mur (Commiphora myrrha: 5gm of powdered Mur mixed with 15gm honey BD for first 3days of menses for 2 consecutive cycles Control Intervention1: Mefenamic acid: Mefenamic acid 250mg TID,

Eligibility

Inclusion criteria

Inclusion criteria: 1.Unmarried women in the age group of 18-25 years. 2.Diagnosed patients of primary dysmenorrhoea.

Exclusion criteria

Exclusion criteria: 1.Irregular menstrual cycle. 2.Organic pelvic pathology. 3.Systemic illness.

Design outcomes

Primary

Measure	Time frame
Reduction in Numarical Rating ScaleTimepoint: after menses for three cycles	—

Secondary

Measure	Time frame
1.Change in Perceived Stress Scale (PSS). 2.Improvement in HR Quality of life assessed by SF-36 questionnaire. Timepoint: 2 months	—

Countries

India

Contacts

Public ContactMariyam Roqaiya

Luqman Unani Medical College Hospital and Research Centre

dr.mroqaiya@gmail.com9632560839

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026